Dnajc13 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
DNAJC13 (DnaJ Heat Shock Protein Family (Hsp40) Member C13), also known as RME-8 (Receptor-Mediated Endocytosis 8), is a co-chaperone protein involved in endosomal trafficking and protein quality control. Mutations in DNAJC13 have been implicated in Parkinson's disease.
| Attribute |
Value |
| Gene Symbol |
DNAJC13 |
| Full Name |
DnaJ Heat Shock Protein Family (Hsp40) Member C13 |
| Aliases |
RME-8, CSP1 |
| Chromosomal Location |
3q22.1 |
| NCBI Gene ID |
23387 |
| Ensembl ID |
ENSG00000126247 |
| UniProt ID |
Q9Y5W2 |
DNAJC13 is a large protein (~2443 amino acids) containing:
- N-terminal J domain (DnaJ/Hsp40 co-chaperone domain)
- Four Hsc70-interacting peptide (HIP) domains
- C-terminal client-binding domain
- Nine tetratricopeptide repeat (TPR) domains
The J domain recruits and stimulates Hsc70 ATPase activity, facilitating the release of folded substrates. The TPR domains mediate interactions with Hsp70/Hsp90 chaperones, while the multiple HIP domains enhance substrate binding capacity.
DNAJC13/RME-8 plays critical roles in:
- Endosomal Trafficking: Regulates early endosome function and recycling through interaction with clathrin and retromer complex components
- Protein Quality Control: Works with Hsp70/Hsc70 chaperone complex to refold or target misfolded proteins for degradation
- Clathrin-Mediated Endocytosis: Involved in receptor internalization and trafficking from plasma membrane to early endosomes
- Lysosomal Delivery: Facilitates cargo delivery to lysosomes via late endosomes
- Retromer Function: Associates with the retromer complex to regulate cargo sorting from endosomes to the trans-Golgi network (TGN)
DNAJC13 functions as a co-chaperone by:
- Recruiting Hsc70 to endosomal membranes
- Stimulating Hsc70 ATP hydrolysis
- Facilitating substrate protein unfolding and refolding
- Coordinating with the retromer complex for cargo recognition
- DNAJC13 N855S and R141Q mutations cause familial Parkinson's disease
- These mutations lead to loss of function in endosomal trafficking
- Enhanced susceptibility to α-synuclein aggregation
- Autosomal dominant inheritance pattern
- Reduced endocytic capacity contributes to α-synuclein accumulation
- Impaired lysosomal function leads to protein aggregate accumulation
- Potential role in Lewy body formation
- May contribute to lysosomal dysfunction in neurodegeneration
- Possible involvement in other synucleinopathies (DLB, MSA)
High expression in:
- Brain (cerebral cortex, hippocampus, substantia nigra, cerebellum)
- Lymphocytes
- Kidney
- Liver
- Lung
- Skeletal muscle
Within the brain, DNAJC13 is expressed in:
- Dopaminergic neurons of the substantia nigra pars compacta
- Cortical pyramidal neurons
- Cerebellar Purkinje cells
- Hippocampal granule cells
- DNAJC13 knockout mice show embryonic lethality
- Conditional knockouts in neurons demonstrate:
- Accumulation of early endosomes
- Impaired receptor trafficking
- Progressive neurodegeneration in dopaminergic neurons
- Wild-type DNAJC13 overexpression protects against α-synuclein toxicity
- Mutant forms (N855S, R141Q) enhance α-synuclein aggregation in models
DNAJC13 mutations represent a rare but important cause of familial Parkinson's disease. Genetic testing for DNAJC13 variants is recommended for patients with:
- Early-onset Parkinson's disease (<50 years)
- Family history of autosomal dominant inheritance
- Atypical features suggesting synucleinopathy
- Gene Therapy: Viral vector delivery of wild-type DNAJC13 to restore function
- Small Molecule Chaperones: Pharmacological chaperones to enhance protein folding and stability
- Endosomal-Lysosomal Pathway Modulators: Drugs targeting upstream trafficking pathways
- Combination Approaches: DNAJC13 therapy combined with α-synuclein-targeting strategies
- Large protein size complicates recombinant protein delivery
- Blood-brain barrier limits small molecule access
- Need for neuron-specific targeting
- Develop brain-penetrant small molecule chaperones
- Validate DNAJC13 replacement in animal models
- Identify biomarkers for therapeutic response
- Study gene-environment interactions in DNAJC13 carriers
The study of Dnajc13 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.